An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.

Goldberg, Stuart L

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. [electronic resource] - Leukemia research reports 2014 - 58-61 p. digital

Publication Type: Journal Article

2213-0489

10.1016/j.lrr.2014.06.003 doi